Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran; Ferdowsi University of Mashhad, Faculty of Sciences, Institute of Applied Zoology, Research Department of Zoological Innovations (RDZI), Mashhad, Iran.
Tissue Cell. 2021 Apr;69:101494. doi: 10.1016/j.tice.2021.101494. Epub 2021 Jan 16.
Bone substitutes are used in nearly half of all musculoskeletal surgeries. The "gold standard" graft is an autograft that is limited by supply and site morbidity. Therefore, allograft sources are the current alternative for clinical practice with some side effects, such as immune responses and risk of disease transmission. In this paper, we have systematically reviewed the development and characterization of decellularized allograft or xenograft-derived scaffolds as bone graft substitutes. The databases of PubMed, Cochrane, Scopus, and Web of Science were searched for experimental studies that investigated the potential of acellular allograft or xenograft-derived scaffold for bone regeneration. The search was finalized on 14 September 2020. The initial electronic database search resulted in a total of 484 studies. During the screening process, 416 studies were excluded due to not meeting the inclusion criteria. Finally, a total of 68 articles were included, in which human or animal tissues have been decellularized for bone tissue generation purposes. Although in most studies, a decellularized bone was used for the generation of a bone scaffold, other decellularized tissues, such as the human amniotic membrane or human adipose tissue, were also used in some researches for this purpose. In 42 studies out of the 68, decellularized bone scaffolds were implanted into in vivo animal models. 8 studies used animal bone tissues as an allograft. 12 studies used human tissues as a xenograft. The studies have shown that decellularized allograft or xenograft scaffolds have high biocompatibility with little or no host response, and can enhance new bone formation. Overall, the results of this study suggest that the decellularized xenograft-derived cancellous bone scaffolds can be considered as alternatives to the autologous bone graft. This systematic review might affect future research directions and the preoperative planning of graft selection.
骨替代物几乎用于所有肌肉骨骼手术的一半。“金标准”移植物是自体移植物,但受供体和部位发病率的限制。因此,同种异体移植物来源是目前临床实践的替代物,但存在一些副作用,如免疫反应和疾病传播的风险。在本文中,我们系统地回顾了脱细胞同种异体或异种移植物衍生支架作为骨移植物替代物的开发和特性。在 2020 年 9 月 14 日,我们在 PubMed、Cochrane、Scopus 和 Web of Science 数据库中搜索了研究去细胞同种异体或异种移植物衍生支架用于骨再生潜力的实验研究。最初的电子数据库搜索共产生了 484 项研究。在筛选过程中,由于不符合纳入标准,有 416 项研究被排除在外。最终,共有 68 篇文章被纳入,其中人类或动物组织已被去细胞化用于骨组织生成。尽管在大多数研究中,使用脱细胞骨来生成骨支架,但在一些研究中,也使用了其他脱细胞组织,如人羊膜或人脂肪组织。在 68 篇文章中的 42 篇中,将脱细胞骨支架植入体内动物模型中。8 项研究使用动物骨组织作为同种异体移植物。12 项研究使用人类组织作为异种移植物。这些研究表明,脱细胞同种异体或异种移植物支架具有很高的生物相容性,宿主反应很少或没有,并且可以增强新骨形成。总的来说,这项研究的结果表明,脱细胞异种移植物衍生的松质骨支架可以作为自体骨移植物的替代品。这篇系统综述可能会影响未来的研究方向和移植物选择的术前规划。